Omeros to Present at Two Upcoming Conferences

  //health-fitness.news-articles.net/content/2012/ .. eros-to-present-at-two-upcoming-conferences.html
  Published in Health and Fitness on Wednesday, March 28th 2012 at 13:11 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

Omeros to Present at Two Upcoming Conferences -- SEATTLE, March 28, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about OMER

SEATTLE, March 28, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: [ OMER ]), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences:

11th Annual Needham Healthcare Conference
April 4, 2012
10:00 a.m. EDT
New York, NY

Future Leaders in the Biotech Industry Conference
April 20, 2012
10:00 a.m. EDT
New York, NY

The presentations will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at [ www.omeros.com ].  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation

RELATED LINKS
[ http://www.omeros.com ]